The treatment with growth hormone receptor antagonist in acromegaly: Effect on vascular structure and function in patients resistant to somatostatin analogues

M. C. De Martino, R. S. Auriemma, G. Brevetti, G. Vitale, V. Schiano, M. Galdieroi, L. Grasso, G. Lombardi, A. Colao, R. Pivonello

Research output: Contribution to journalArticle

Abstract

Background: Acromegaly is known to be associated to vascular damage characterized by an increase of vascular wall thickness and an impairment of vascular function. Aim: The aim of this study was to evaluate the effect of medical treatment with the GH receptor antagonist pegvisomant on vascular structure and function in acromegalic patients resistant to somatostatin analogues. Patients: Ten patients (4 males and 6 females, 28-58 yr) and 20 sex-, age-, and body mass index-matched healthy controls entered the study. All patients were treated for 18 months with pegvisomant at doses ranging from 10 to 40 mg/day. Outcome measures: Primary outcome measures were measurement of carotid arteries intima-media thickness (IMT), and brachial arteries flow mediated dilation (FMD); secondary outcome measures were blood pressure, blood glucose and lipids levels. Results: Carotid arteries maximal IMT was significantly higher in patients than in controls at baseline (1.18±0.59 vs 0.69±0.13, p=0.001) and slightly, but not significantly, decreased after treatment (0.97±0.17). Brachial arteries FMD was significantly lower in patients than controls at baseline (7.5±2.5 vs 13.1 ±1.4, p

Original languageEnglish
Pages (from-to)663-670
Number of pages8
JournalJournal of Endocrinological Investigation
Volume33
Issue number9
DOIs
Publication statusPublished - Oct 2010

Keywords

  • Acromegaly
  • Cardiovascular risk
  • Echo-cloppler
  • Flow-mediated dilation
  • FMD
  • GH
  • GH receptor antagonist
  • IGF
  • IMT
  • Intima-media thickness
  • Pegvisomant

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'The treatment with growth hormone receptor antagonist in acromegaly: Effect on vascular structure and function in patients resistant to somatostatin analogues'. Together they form a unique fingerprint.

  • Cite this